Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Central & Western Europe has been growing steadily in recent years.
Customer preferences: Patients in Central & Western Europe are increasingly seeking personalized treatments, and this is driving innovation in the oncology drugs market. There is also a growing demand for drugs that have fewer side effects and are more effective in treating cancer.
Trends in the market: Germany is the largest market for oncology drugs in Central & Western Europe, followed by France and the United Kingdom. The market is expected to continue to grow due to an aging population and an increase in the prevalence of cancer. There is also a growing trend towards the use of immunotherapy in the treatment of cancer, which is expected to drive growth in the market.In Germany, there has been a shift towards the use of biosimilars in the treatment of cancer, as they offer a more cost-effective alternative to branded drugs. In France, there has been a focus on the development of targeted therapies, which are designed to attack specific cancer cells. The United Kingdom has been investing in the development of new cancer drugs, as well as improving access to existing treatments.
Local special circumstances: The healthcare systems in Central & Western Europe vary from country to country, and this can have an impact on the oncology drugs market. For example, in Germany, the government regulates drug prices, which can limit the profitability of pharmaceutical companies. In France, there is a centralized system for drug approval and reimbursement, which can make it difficult for new drugs to enter the market.
Underlying macroeconomic factors: The economy in Central & Western Europe has been growing slowly in recent years, which has had an impact on the healthcare sector. Governments in the region have been under pressure to reduce healthcare spending, which has led to a focus on cost-effective treatments. However, the aging population and the increasing prevalence of cancer are expected to continue to drive growth in the oncology drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
